Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT2 | O60551 | 2/20 | 0.42 |
| ▸ | NMT1 | P30419 | 2/20 | 0.42 |
| ▸ | NPY4R | P50391 | 13/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.40 |
| ▸ | NPY1R | P25929 | 9/20 | 0.40 |
| ▸ | NPY2R | P49146 | 6/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5086123 | 0.98 | NMT2 (0.42) | NMT2NMT1NPY4RNPY5RNPY1R | |
| SCHEMBL5598740 | 0.89 | NMT2 (0.43) | NMT2NMT1NPY4RNPY5RNPY1R | |
| SCHEMBL2241867 | 0.89 | NMT1 (0.42) | NMT2NMT1NPY4RNPY5RNPY1R | |
| SCHEMBL4589289 | 0.86 | NMT1 (0.42) | NMT2NMT1NPY4RNPY5RNPY1R | |
| SCHEMBL2244099 | 0.85 | NPY4R (0.44) | NMT2NMT1NPY4RNPY5RNPY1R | |
| SCHEMBL18264779 | 0.85 | TLR2 (0.44) | NMT2NMT1NPY4RNPY5RNPY1R | |
| SCHEMBL4588680 | 0.83 | NPY4R (0.44) | NMT2NMT1NPY4RNPY5RNPY1R | |
| SCHEMBL18264761 | 0.83 | NPY4R (0.46) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL18264812 | 0.80 | NPY4R (0.46) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL22618583 | 0.79 | NPY4R (0.40) | NPY4RNPY5RNPY1RNPY2RSIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249042-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYELASHES AND EYEBROWS | PROCYTE CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| EP-1613302-B1 | PRESERVED AND STABLE COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND METHODS RELATED THERETO | PROCYTE CORP (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7179789-B2 | Compositions and methods for treatment of rosacea | PROCYTE CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| US-7128923-B2 | Preserved and stable compositions containing peptide copper complexes and method related thereto | PROCYTE CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060052287-A1 | Polyethylene glycol - peptide copper complexes and compositions and methods related thereto | PROCYTE CORPORATION (US) | 2006-03-09 | — | — | US | disclosed |
| US-20050209130-A1 | Compositions and methods for treatment of rosacea | PROCYTE CORPORATION (US) | 2005-09-22 | — | — | US | disclosed |
| US-20050197282-A1 | for topical administration of peptide copper complex with corticosteroids, coal tar, anthralin, calcipotriene, and tazarotene; dermatology; cosmetics | PROCYTE CORPORATION (US) | 2005-09-08 | — | — | US | disclosed |
| US-6927206-B2 | Compositions and methods for treatment of rosacea | PROCYTE CORPORATION (US) | 2005-08-09 | — | — | US | disclosed |
| US-6927205-B2 | Compositions and methods for treatment of psoriasis | PROCYTE CORPORATION (US) | 2005-08-09 | — | — | US | disclosed |
| EP-0765152-B1 | STIMULATION OF HAIR GROWTH BY PEPTIDE-COPPER COMPLEXES | PROCYTE CORP (US) | 2001-11-07 | — | — | EP | disclosed |
| EP-0765152-A1 | STIMULATION OF HAIR GROWTH BY PEPTIDE-COPPER COMPLEXES | PROCYTE CORPORATION (US) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995035085-A1 | STIMULATION OF HAIR GROWTH BY PEPTIDE-COPPER COMPLEXES | PROCYTE CORPORATION (US) | 1995-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209130-A1 | Compositions and methods for treatment of rosacea | CUTA, AOC1, RCN1 | NMT2 3869/4885NMT1 4107/4885NPY4R 811/4885 |
| US-20060052287-A1 | Polyethylene glycol - peptide copper complexes and compositions and methods related thereto | NGLY1, CUTA, TFRC | NMT2 1991/4885NMT1 1434/4885NPY4R 1065/4885 |
| US-20100249042-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYELASHES AND EYEBROWS | CUTA, TYR, EYA3 | NMT2 2644/4885NMT1 3403/4885NPY4R 785/4885 |
| US-20050197282-A1 | for topical administration of peptide copper complex with corticosteroids, coal tar, anthralin, calcipotriene, and tazarotene; dermatology; cosmetics | PTH1R, TSLP, CYP27B1 | NMT2 3870/4885NMT1 3305/4885NPY4R 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.